Fellowship, University of Washington, Infectious Diseases, 1977.
EIS Officer, Centers for Disease Control and Prevention (CDC), Internal Medicine Training, 1975.
Residency, University of Michigan, Medical Center Hospitals, Internal Medicine, 1973.
M.D., University of Michigan, 1971.
The herpes virus research program at the University of Washington involves studies in HSV, CMV, HHV-6 and HHV-8. The genital HSV program has been the most longstanding, having had continuous NIH funding since 1978. This program involves clinical investigations of HSV reactivation and transmission, laboratory based studies on the cellular immunology of HSV, and characterization of HSV-HIV interactions. In the last few years, the laboratory has focused on developing an HSV vaccine by defining the T-cell responses to HSV, especially cytotoxic T-cell responses as a means of developing CTL-based vaccines for immunotherapy or prophylaxis of genital HSV. The laboratory based programs involve collaborations with Drs. Jia Zhu, Research Assistant Professor; David Koelle, Professor of Medicine; Keith Jerome, Professor of Laboratory Medicine, University of Washington and now Head of the Diagnostic Virology Division; and Christine Posavad, Senior Scientist at the Hutchinson Center. The Clinical Research Program in genital herpes is directed by Dr. Anna Wald, Professor of Medicine, University of Washington and Dr. Christine Johnston, Assistant Professor of Medicine, University of Washington. Dr. Wald is medical director of the Viral Disease Clinic, a specialty clinic dedicated to a wide range of clinical studies on HSV infection, including resolution frequency, vaccine efficacy and technology development.
The program in HHV-8 infection encompasses studies of the transmission of HHV-8 and the mechanism by which HHV-8 induces Kaposi’s sarcoma. This work is done with Dr. Corey Casper, Associate Member at the Hutchinson Center. Clinical trials for HHV-8 prevention are conducted in the newly formed Uganda Program on Cancer and Infectious Diseases under the direction of Dr. Orem Jackson of the Uganda Cancer Institute and Dr. Corey Casper and Dr. Warren Phipps at the Hutchinson Center.
The Vaccine and Infectious Disease Division (VIDD) of the Hutchinson Center is home to many researchers studying prevention of CMV and HHV-6 infections in the immunocompromised host and the role these infections play in the morbidity of HSCT. Dr. Michael Boeckh, Professor of Medicine heads research on CMV infection in collaboration with Dr. Steven Pergam, Associate Professor in Medicine.
The HIV research program directed by Dr. Corey includes both laboratory and clinical investigation. Dr. Corey is the co-PI of the NIAID supported HIV Vaccine Trials Network (HVTN), a global network of clinical trial sites and laboratories dedicated to phase I-III trials of candidate HIV vaccines and other preventative and treatment options. Other faculty members involved in the effort are Drs. Juliana McElrath, Peter Gilbert and Jim Kublin. Training opportunities for postdoctoral fellows interested in learning vaccine biology and clinical trial research are available within the network.
Dr. Corey is a member of numerous committees and editorial boards in areas of infectious diseases, HIV infection, and HIV vaccines. He is a member of the National Cancer Institute Board of Scientific Counselors, Basic Sciences.
American Epidemiological Society
American Federation for Clinical Research
American Society of Clinical Investigation
Association of American Physicians
Infectious Diseases Society of America
Institute of Medicine
Western Association of Physicians
Honors and Awards
2012, Recipient, 2012 Cubist-ICAAC Award, American Society for Microbiology
2012, Elected, Member, American Academy of Arts and Sciences
2011, Lifelong AIDS Alliance "Ned Behnke Leadership Award"
2008, Elected, National Academy of Sciences, Institute of Medicine, National Academy of Sciences
2007-2010, Co-Director, Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division
2007-2010, Senior Vice President, Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division
1996-2010, Head, Fred Hutchinson Cancer Research Center, Clinical Research Division, Infectious Disease Sciences
1978-2010, Head, Virology Division, Department of Laboratory Medicine, School of Medicine, University of Washington
Higher T cell responses induced by DNA/rAd5 HIV-1 preventive vaccine are associated with lower HIV-1 infection risk in an efficacy trial.. The Journal of infectious diseases.. 2017.
Bronchoalveolar Lavage DNA Quantification in Cytomegalovirus Pneumonia after Hematopoietic Cell Transplantation.. The Journal of infectious diseases.. 2017.
Preventing acquisition of HIV is the only path to an AIDS-free generation.. Proceedings of the National Academy of Sciences of the United States of America. 114(15):3798-3800.. 2017.
Dynamics of persistent oral cytomegalovirus shedding during primary infection in Ugandan infants.. The Journal of infectious diseases.. 2016.
Approaches to preventative and therapeutic HIV vaccines.. Current opinion in virology. 17:104-109.. 2016.
Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap.. Clinical and vaccine immunology : CVI. 23(6):496-506.. 2016.
In Situ Detection of Regulatory T Cells in Human Genital Herpes Simplex Virus Type 2 (HSV-2) Reactivation and Their Influence on Spontaneous HSV-2 Reactivation.. The Journal of infectious diseases. 214(1):23-31.. 2016.
No Evidence of Pritelivir Resistance Among Herpes Simplex Virus Type 2 Isolates After 4 Weeks of Daily Therapy.. The Journal of infectious diseases. 214(2):258-264.. 2016.
Selection of HIV vaccine candidates for concurrent testing in an efficacy trial.. Current opinion in virology. 17:57-65.. 2016.
Current Concepts for Genital Herpes Simplex Virus Infection: Diagnostics and Pathogenesis of Genital Tract Shedding.. Clinical microbiology reviews. 29(1):149-61.. 2016.
Mathematical modeling of herpes simplex virus-2 suppression with pritelivir predicts trial outcomes.. Science translational medicine. 8(324):324ra15.. 2016.
Prospective characterization of the risk factors for transmission and symptoms of primary human herpesvirus infections among Ugandan infants.. The Journal of infectious diseases.. 2016.
Herpes Simplex Virus Type 1 Shedding in Tears and Nasal and Oral Mucosa of Healthy Adults.. Sexually transmitted diseases. 43(12):756-760.. 2016.
Image analysis for accurately counting CD4+ and CD8+ T cells in human tissue.. Journal of virological methods. 222:117-21.. 2015.
Immune correlates of vaccine protection against HIV-1 acquisition.. Science translational medicine. 7(310):310rv7.. 2015.
Genital Herpes Simplex Virus Type 2 Shedding Among Adults With and Without HIV Infection in Uganda.. The Journal of infectious diseases.. 2015.
Are Clade Specific HIV Vaccines a Necessity? An Analysis Based on Mathematical Models. EBioMedicine. 2(12):2062-9.. 2015.
Reduced Mortality of Cytomegalovirus Pneumonia After Hematopoietic Cell Transplantation Due to Antiviral Therapy and Changes in Transplantation Practices.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.. 2015.
Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies.. Science (New York, N.Y.).. 2015.
Use of placebos in Phase 1 preventive HIV vaccine clinical trials.. Vaccine. 33(6):749-52.. 2015.